Home › Mieloma multiplo › Indiana
Studi clinici su Mieloma multiplo nello stato di Indiana
19 studi su Mieloma multiplo cercano partecipanti presso sedi nello stato di Indiana.
Città nello stato di Indiana
Testo ufficiale dello studio (inglese)
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
- Study Site 101, Fort Wayne
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT07582432A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Franciscan Health, Indianapolis
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07518186A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Indiana University, Indianapolis
In reclutamentoFase 4
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT05201781A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Genesis Medical Research, Dyer
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 set 2026 · NCT07477587A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Fort Wayne Medical Oncology And Hematology /ID# 278141, Fort Wayne
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07095452TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Community Health Network (The University of Texas MD Anderson Cancer Center), Indianapolis
In reclutamentoFase 2
Età 12 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT02693535Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Indiana University Health Arnett, Inc., Lafayette
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 21 set 2026 · NCT07648264Collection of Tissue Samples for Cancer Research
- Indiana University - Purdue, Indianapolis
In reclutamentoStudio osservazionale
2 Months · Tutti i sessi · Aggiornato il 16 set 2026 · NCT00900198MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Community Health Network, Inc., Indianapolis
- Community Health Network, Inc., Indianapolis
- Community Health Network, Inc., Indianapolis
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 ago 2026 · NCT06152575Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- IU Health North Hospital, Carmel
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- IU Health Methodist Hospital, Indianapolis
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 19 ago 2026 · NCT04566328A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- Indiana University, Indianapolis
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 12 ago 2026 · NCT07280013A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Indiana University Health, Indianapolis
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 6 ago 2026 · NCT07284758A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Fort Wayne Medical Oncology And Hematology /ID# 268179, Fort Wayne
- Franciscan St. Francis Health /ID# 280928, Indianapolis
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 13 lug 2026 · NCT05650632A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- Indiana University Health Simon Cancer Center, Indianapolis
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 lug 2026 · NCT05137054Integrated Cancer Repository for Cancer Research
- Parkview Research Center, Fort Wayne
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età da 19 a 110 · Tutti i sessi · Aggiornato il 29 giu 2026 · NCT02012699Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
- Community Health Network, Indianapolis
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 giu 2026 · NCT04068597Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- IU Health North Hospital, Carmel
- Northwest Cancer Center - Main Campus, Crown Point
- Northwest Oncology LLC, Dyer
- e altri 8
In reclutamentoFase 3
Tutte le età · Tutti i sessi · Aggiornato il 10 giu 2026 · NCT05561387cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Baptist Floyd, New Albany
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età 40 e oltre · Tutti i sessi · Aggiornato il 20 gen 2026 · NCT05366881The Indiana Myeloma Registry
- Indiana University Simon Cancer Center, Indianapolis
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 nov 2025 · NCT03616483Fonte: ClinicalTrials.gov, dati recuperati il 4 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.